Cohort Follow-up: Progression and Consequences of Chronic Kidney Disease.

NCT04070885 — Completed, 210 participants, University Hospital, Bordeaux

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Registry	NCT04070885, acronym NéphroTest
Status	Completed
Study type	Observational
Enrollment	210 (Actual)
Sponsor	University Hospital, Bordeaux (Other)
Conditions	Chronic Renal Diseases, Renal Function Disorder
Interventions	Blood sample, Urine sample (Procedure)
Dates	start 2011-01-05, primary completion 2015-03-20, completion 2015-03-20, first posted 2019-08-28, last updated 2019-08-28

-Summary

This study aims to conduct a prospective collection of clinical and para-clinical data in patients with Chronic Renal Diseases to identify disease progression factors, markers of renal function, and the pathophysiology of Chronic Renal Diseases complications.

Expand all sections · Collapse all

+Detailed description

Chronic Renal Diseases have a growing incidence and prevalence in France, with significant consequences in terms of morbidity and mortality, especially cardiovascular, and Public Health.

It is necessary to know better:

* the mechanisms leading to the progression of the Chronic Renal Diseases
* markers to quantify renal function and progression of the Chronic Renal Diseases
* the pathophysiology of Chronic Renal Diseases complications, cardiovascular, nutritional, or mineral metabolism in particular.

+Arms and interventions

Blood sample (Procedure): A dry tube of 7 ml of blood, two 4 ml EDTA tubes, a 4 ml heparinized tube and an 8.5 ml ACD-A tube will be collected from the patient.
Urine sample (Procedure): The urine will be taken from three 15 ml tubes.

+Outcome measures

Primary outcomes

Estimated Glomerular Filtration Rate measurement [At 1 year after inclusion]: by isotope technique
Estimated Glomerular Filtration Rate measurement [At 2 year after inclusion]: by isotope technique
Measured Glomerular Filtration Rate [At 1 year after inclusion]: by isotope technique
Measured Glomerular Filtration Rate [At 2 years after inclusion]: by isotope technique

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Patients with Chronic Renal Disease, stage 2 to 5, non-dialysis patients over the age of 18,
* followed in the Nephrology Department of the Bordeaux University Hospital
* agreeing to participate in NephroTest
* affiliated with social security.

Exclusion Criteria:

* Patients under 18 years
* Patients with acute or rapidly progressive renal failure
* Patients with severe comorbidities or comorbidities that are life-threatening in the short term (<1 year)
* Patients who did not give their written consent to be included in the study
* Major incapacitated patients and psychiatric patients admitted to hospital

+Investigators

Christian COMBE, Pr, Principal investigator, University Hospital, Bordeaux